Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-10-22
2000-04-04
Elliott, George C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 243, 536 2433, 435 911, C07H 2102, C07H 2104
Patent
active
060463198
ABSTRACT:
A synthetic nuclease resistant antisense oligodeoxynucleotide capable of selectively modulating expression of human tumor necrosis factor-alpha by targeting exon sequences flanking donor splice sites, thereby regulating expression of TNF-.alpha. in a patient in need of such therapy is provided. In an embodiment either AS-ODN having the sequence set forth in SEQ ID No:4 or SEQ ID No:6 or a combination thereof can be used. The AS-ODN is administered either as the active ingredient in a pharmaceutical composition or by utilizing gene therapy techniques as an expression vector.
REFERENCES:
Crooke, S., Basic Principles of Antisense Therapeutics, Springer-Verlag Berlin Heidelberg New York, Jul. 1998.
Gura T., Antisense Has Growing Pains, Science, vol. 270, pp. 575-577, Oct. 1995.
Crooke, S. et al., Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, vol. 15, p. 522, Jun. 1997.
Branch, A., A good antisense molecule is hard to find, TIBS vol. 23, pp. 47-49, Feb. 1998.
Mayne Michael B.
Power Christopher
Elliott George C.
Epps Janet L.
University Technologies International Inc.
LandOfFree
Antisense oligodeoxynucleotides regulating expression of TNF-.al does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligodeoxynucleotides regulating expression of TNF-.al, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligodeoxynucleotides regulating expression of TNF-.al will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-366474